Acquisitions:
1. Poly Medicure to acquire 90% stake in PendraCare Group for US$19.4 million (€ 18.3 million).
2. Bartronics India acquires 15% stake in Huwel Life Sciences for US$6 million (INR 50 Crore).
3. Lupin acquires VISUfarma to strengthen specialty ophthalmology portfolio.
4. Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment.
5. Novartis to gain heart drug in US$1.4 billion deal for Tourmaline Bio.
6. Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs.
7. Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH.
Licensing:
1. Glenmark in-licenses cancer drug from Hengrui Pharma for US$18 million upfront payment. Glenmark will also pay Hengrui regulatory and commercial milestone payments of up to US$1.093 billion besides royalties.
2. Ipca Laboratories and BioSimilar Sciences PR strike major Tech Transfer Agreement for their Biosimilars to be manufactured in the U.S..
3. Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market.
4. Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC.
5. Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea.
6. Mycenax and SPERA PHARMA Forge Strategic Alliance to Streamline ADC Drug Substance and Drug Product Manufacturing Services.
7. Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893.
8. OMass Therapeutics Signs Exclusive Collaboration and Licence Agreement with Genentech for Inflammatory Bowel Disease Therapies
Investments:
1. Modus Therapeutics raises approximately US$2.6 million (SEK 28.3 million). The net proceeds will primarily be used to finance clinical activities, including the ongoing phase II study.
2. AusperBio raises US$73 million to advance hep B candidate.
Co-development:
1. Strides signs co-development deal with Kenox CDMO to expand nasal spray portfolio for US market combining Strides’ commercial strengths with Kenox’s expertise in Orally Inhaled and Nasal Drug Products (OINDPs).
2. TegMine Therapeutics Collaborates with Boehringer Ingelheim to Advance 2-Factor Antibody System for Cancer.
Aagami Updates:
1. Aagami successfully completed Asia Bio Partnering Forum 2025 (Singapore) with 20+ one-to-one meetings .
2. We are pleased to announce that the U.S. Food and Drug Administration (FDA) has granted approval for our client’s patented lidocaine patch developed for the relief of pain associated with post-herpetic neuralgia (PHN).
3. Aagami to participate in the following partnering conferences soon. Please contact us to set up a meeting.
a. Bio Japan | OCT 08-10, 2025 | PACIFICO Yokohama
b. BIOPLUS-INTERPHEX KOREA| OCT 15-17, 2025 | COEX Seoul
c. BIO-EUROPE | NOV 03-05, 2025 | Vienna, Austria
d. BIOTECH SHOWCASE | Jan 12-14, 2026 | San Francisco
Select opportunities available with us:
For Partnering/Licensing/ Co-development:
1. US Licensing: FDA Approved Patented Lidocaine Patch using proprietary technology.
2. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.
3. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients under 72 years of age).
5. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
6. Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.
7. Partnering/Licensing/JV: Small molecule Drug for Myelodysplastic Syndrome (MDS) Two human trials (n=6 and n=30) completed in Australia. The trial results will be presented at the 3rd World Congress (Oct15-18) in Rio de Janeiro, Brazil.
For Acquisition:
1. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.
2. Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.
3. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc. - for Next-generation biologics.
4. Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia. Two human trials (n=6 and n=30) completed in Australia. The trial results will be presented at the 3rd World Congress (Oct15-18) in Rio de Janeiro, Brazil.
For Investment:
1. High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US$70 million raised in current round, our client is offering special terms to invest in current B-4/B-5 round. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout.
Hope you found the content useful. We welcome your feedback and queries.